Advertisement

Molecular and Cellular Biochemistry

, Volume 91, Issue 1–2, pp 159–165 | Cite as

Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes

  • S. Tsuyoshi Ohnishi
  • Kenneth K. Sadanaga
  • Masayuki Katsuoka
  • William P. Weidanz
Invited Paper

Abstract

The effects of several membrane-acting drugs on malaria and sickle cell anemia was studied. In the initial experiments, propranolol and W-7 were shown to increase red cell density.In vitro, these drugs inhibited the growth ofP. falciparum. However,in vivo experiments using the murine malarial parasite,P. vinckei, demonstrated little, if any, anti-parasite activity with the doses of drugs employed. Subsequently, prostaglandin oligomeric derivatives were found to inhibit the growth ofP. falciparum in vitro andP. vinckei in vivo. Since prostaglandin oligomers inhibited the formation of dense, dehydrated cells (irreversible sickle cells), they may also have therapeutic efficacy in sickle cell anemia.

Key words

propranolol W-7 prostaglandin oligomers malarial parasites Sickle cell anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peters W: Antimalarial drug resistance: an increasing problem. British Medical Bulletin 38: 187–192, 1982Google Scholar
  2. 2.
    Friedman MJ: Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci (USA) 75: 1994–1997, 1978Google Scholar
  3. 3.
    Friedman M, Roth EF, Nagel RL, Trager W: The role of hemoglobins C, S, and NBaly in the inhibition of malaria parasite development in vitro. J Trop Med Hyg 28: 777–780, 1979Google Scholar
  4. 4.
    Eaton JW, Skelton TD, Swofford HS, Kolpin CE, Jacob HS: Elevated erythrocyte calcium in sickle cell disease. Nature 246: 105–106, 1973Google Scholar
  5. 5.
    Palek J: Calcium accumulation during sickling of hemoglobin S (HbSS) red cells. Blood 42: 988, 1973Google Scholar
  6. 6.
    Palek J, Thomae D, Ozog D: Red cell calcium content and transmembrane calcium movements in sickle cell anemia. J Lab Clin Med 89: 1365–1374, 1977Google Scholar
  7. 7.
    Lew VL, Hockaday A, Sepulveda, MI, Somlyo AP, Somlyo AV, Ortiz OE, Bookchin RM: Compartmentalization of sickle cell calcium in endocytic inside-out vesicles. Nature 315: 586–589, 1985Google Scholar
  8. 8.
    Ohnishi ST: The role of calmodulin in sickle cell anemia.In ‘Calmodulin Antagonists and Cellular Physiology’ (Hidaka H, Hartshorne DJ, eds.) pp. 161–183, Academic Press, N.Y., 1985Google Scholar
  9. 9.
    Ohnishi ST, Horiuchi KY, Horiuchi K: Nitrendipine, nifedipine and verapamil inhibit thein vitro formation of irreversibly sickled cells. Pharmacology 32: 248–256, 1986Google Scholar
  10. 10.
    Ohnishi ST, Horiuchi KY, Horiuchi K: The mechanism ofin vitro formation of irreversibly sickled cells and modes of action of its inhibitors. Biochim Biophys Acta 886: 119–129, 1986Google Scholar
  11. 11.
    Ohnishi ST: Why do sickle cells sickle into a sickle shape? in ‘Approaches to the Therapy of Sickle Cell Anemia’, (Beuzard Y, Charache S, Galacteros F, eds.) Les Editions INSERM, Colloque Vol. 141, pp 337–354 (1986) Creteil, France.Google Scholar
  12. 11.3.
    Friedman MJ, Proc Natl Acad Sci USA 75, 1994–1997, 1978Google Scholar
  13. 12.
    Ohnishi ST, Katsuoka M, Hidaka S: A prostaglandin oligomeric derivative inhibits activities of phospholipase and protease: A possible mechanism of membrane protection during ischemia. Cell Biochem Function 7: 51–55, 1989Google Scholar
  14. 13.
    Jensen JB, Trager W: Plasmodium falciparum in culture: use of outdated erythrocytes and description of the candle jar method. J Parasitology 63: 883–836, 1977Google Scholar
  15. 14.
    Grun JL, Weidanz BP: Cultivation of plasmodium falciparum in commercially available sera depleted of natural antibodies reactive with human erythrocytes. J Parasit 73: 384–388, 1987Google Scholar
  16. 15.
    Ohnishi ST: Inhibition of thein vitro formation of irreversibly sickled cells by cepharanthine. British J. of Haematology 55: 665–671, 1983Google Scholar
  17. 16.
    Manninen V: Movements of sodium and potassium ions and their traces in propranolol-treated red cells and diaphragm muscle. Acta Physiol Scand Suppl 355: 1–76, 1970Google Scholar
  18. 17.
    Tanabe K, Mikkelsen RB, Wallach DF: Calcium transport of plasmodium chabaudi-infected erythrocytes. J Cell Biol 93: 680–684, 1982Google Scholar
  19. 18.
    Wasserman M, Alarcon C, Mendoza PM: Effects of Ca++ depletion on the asexual cell cycle of plasmodium falciparum. Am J Trop Med Hyg 31: 711–717, 1982Google Scholar
  20. 19.
    Dunn MJ: Alterations of red blood cell sodium transport during malarial infection. J Clin Invest 48: 674–684, 1969Google Scholar
  21. 20.
    Mikkelsen RB, Tanabe K, Wallach D: Membrane potential of plasmodium-infected erythrocytes. J Cell Biol 93: 685–689, 1982Google Scholar
  22. 21.
    Krungkrai J, Yuthavong Y: Enhanced Ca2+ uptake by mouse erythrocytes in malarial (plasmodium Berghei) infection. Molecul Biochem Parasitol 7: 227–235, 1983Google Scholar
  23. 22.
    Scheibel LW, Colombani PM, Hess AD, Aikawa M, Atkinson CT, Milhous WK: Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): Implication for drug design. Proc Natl Acad Sci USA 84: 7310–7314, 1987Google Scholar
  24. 23.
    Method of preventing the growth of malaria parasites in erythrocytes. United States Patent No. 4,681,899, 1987Google Scholar
  25. 24.
    Ohnishi ST, Ohnishi N, Oda Y, Katsuoka M: Prostaglandin derivatives inhibit the growth of malarial parasite in mice. Cell Biochem Function 7: 105–109, 1989Google Scholar
  26. 25.
    Pasvol G, Wilson RJM: The interaction of malaria parasites with red blood cells. British Medical Bulletin 38: 133–140, 1982Google Scholar
  27. 26.
    Kometani T, Devlin TM, Ohnishi ST: Studies of the cation binding properties of an oligomeric derivative of prostaglandin B1. Prostaglandins, Leukotrienes and Essential Fatty Acids 317: 37–43, 1989Google Scholar
  28. 27.
    Ohnishi ST, Teiji Tominaga, Katsuoka M: Inhibition of ischemic brain edema formation by post-ischemic administration of a prostaglandin oligomer. Prostagland leuko essent fat acids 37: 107–111, 1989Google Scholar
  29. 28.
    Ohnishi ST, Katsuoka M: Protection of the heart from ischemia by a new oligomeric derivative of prostaglandin E1. Prostagland Leuko Essent Fat Acids 36: 159–163, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • S. Tsuyoshi Ohnishi
    • 1
  • Kenneth K. Sadanaga
    • 1
  • Masayuki Katsuoka
    • 1
  • William P. Weidanz
    • 2
  1. 1.Membrane Research InstituteMembrane Research FoundationPhiladelphia
  2. 2.Department of Microbiology and ImmunologyHahnemann University School of MedicinePhiladelphiaUSA

Personalised recommendations